Wednesday 12 March 2014 – GSK Vaccines, Wavre, Belgium
Programme

This workshop is sponsored by:

You can download this program from the pdf in attachment at the bottom of this page.

8:00-8:50
 
Coffee
 
 
8:50-9:00
 
Welcome
 
JM. Wilkin,
GSK Vaccines, Belgium
Morning session: Introductory lectures

9:00-9:40
 
Nucleotide therapies: Past failures and
future challenges
 
L. Coney,
Huntingdon Life Sciences, UK
9:40-10:20 Safety evaluation of gene therapy products
including inhaled products
M.Mc Elroy
Charles River Laboratories, UK
 
10:20-10:45 Regulatory perspective on the safety assessment
of oligonucleotides and gene therapies
C. Beuneu
Federal Agency for Medicines
and Health Products, Belgium
10:45-11:05
 
Coffee break
 

 
11:05-11:35 The personalized medicine approach in orphan
disease: development of oligonucleotides for
the treatment of Duchenne's Muscular Distrophy
 
C. den Besten
Prosensa, The Netherlands
11:35-12:05
 
Toxicologic pathology of anitsense
oligonucleotides
 
C. Sobry,
CitoxLab, France
 
12:05-12:45 Non-GLP pharmacology and the GLP toxicology
studies to support the use of CpG as adjuvant
in anti-nicotine and anti-IgE therapeutic vaccines
 
M. McCluskie,
Pfizer, Canada
12:45-13:45
 
Lunch and networking
 
 
Afternoon session: Case studies analysis

13:45-14:00
 
Introduction to breakout sessions  
14:00-15:00 Breakout sessions
 
15:00-15:20
 
Coffee break
 
 
15:20-16:50
 
Case study reporting and discussion
 

 
16:50-17:00
 
Concluding remarks
 
M. Martens
President BelTox
Organizing Committee : Judith Baumeister (Ablynx, B), Michaela Damsten, Frédérique
Delannois, Camille Planty and
Lawrence Segal (GSK Vaccines), Miek Desmidt,
Ad Knaapen and
Ilham Smyej (Johnson & Johnson, B), Annick Cauvin and Miranda
Cornet (UCB Pharma, B)